Testosterone governs wanting more than it governs working.
Testosterone has a real and consistent effect on sexual desire. Its effect on erections is smaller and concentrated in men who are genuinely deficient.
Testosterone governs wanting more than it governs working. That one distinction accounts for most of what confuses men about hormones and sex: why interest can return on treatment while erections do not, why sildenafil succeeds where testosterone fails, and why the two largest trials in the field found improvement in one domain and not the other.
Four systems, not one
"Sexual function" bundles together four processes that run on different machinery. Desire is substantially androgen-dependent, and it is testosterone's clearest domain. Arousal and erection are a vascular and neurological event — nitric oxide, smooth muscle relaxation, arterial inflow, venous trapping — in which testosterone supports the tissue while the mechanics remain largely plumbing. Orgasm is a spinal and cerebral reflex, poorly understood and weakly linked to testosterone. Ejaculation is a separate reflex again, with its own neurology.
Any combination is possible: strong desire with unreliable erections, reliable erections with no interest, both intact with delayed orgasm. Treating all four as one dial is the error that produces disappointed patients, and it is also why two well-conducted trials can appear to contradict each other.
What the trials found
The Testosterone Trials, in men with unambiguous deficiency, found significant improvement across all three sexual domains: sexual activity with a treatment effect of 0.58 (95% CI 0.38–0.78), sexual desire 2.93 (95% CI 2.13–3.74), and erectile function 2.64 (95% CI 1.68–3.61), all p<0.001. TRAVERSE, in 5,246 older men at high cardiovascular risk, found sexual activity improved by 0.49 acts per day at six months (95% CI 0.19–0.79) and desire improved significantly, with no significant difference in erectile function (p=0.443; a 0.6-point between-group difference at twelve months and −0.2 at twenty-four).
Desire improved in both trials. Erections improved in one and not the other, and the difference is baseline severity. A 2024 meta-analysis by Xu and colleagues, pooling 12 randomised trials in 1,466 men, found testosterone improved erectile function scores by a weighted mean of 3.26 IIEF points (95% CI 1.65–4.88, p<0.0001). The severity gradient comes from a larger meta-analysis — Corona and colleagues in European Urology, 14 placebo-controlled trials in 2,298 men — which found the improvement was 2.95 points (95% CI 1.86–4.03) in men below 8 nmol/L against 1.47 points (95% CI 0.90–2.03) in men below 12 nmol/L, a significant difference between subgroups (Q=5.61, p=0.02). The benefit concentrates in marked deficiency and fades toward nothing in the borderline range.
TRAVERSE enrolled men with milder deficiency, an average age around 65, and a heavy burden of diabetes and vascular disease. Most of their erectile dysfunction was not hormonal, so correcting the hormone did not correct it. The practical expectation follows from where a man sits on that gradient: the more clearly deficient he is, the more likely testosterone helps his erections, and a man of 60 with hypertension, diabetes and a testosterone of 320 is more likely to notice desire than function.
Adding testosterone to sildenafil
The proposition is reasonable. If a man with low testosterone responds inadequately to a PDE5 inhibitor, adding testosterone might rescue the response. The best trial says it does not. Spitzer and colleagues, in the Annals of Internal Medicine in 2012, took around 140 men aged 40 to 70 with erectile dysfunction and low testosterone, optimised them on sildenafil first, then randomised them to testosterone gel or placebo for fourteen weeks. The primary erectile function outcome showed a mean difference of 2.2 points (95% CI −0.8 to 5.1, p=0.150), and desire, intercourse frequency and satisfaction were similarly unmoved.
Older and smaller positive literature exists, including a 2004 randomised trial reporting benefit from adding testosterone in hypogonadal sildenafil non-responders. It is smaller and of lower quality than Spitzer, so the evidence is mixed with the best trial negative.
Morning erections
Loss of morning erections is one of the three symptoms the European Male Ageing Study found independently associated with testosterone, alongside low desire and erectile dysfunction — three of 32 candidate symptoms screened in 3,369 men. That makes it worth reporting to a clinician. It is not a test: no sensitivity or specificity figures are available, and morning erections vary with sleep quality, alcohol, age and medication. Their absence is a reason to investigate and their presence is not a clearance.
Erectile dysfunction as a cardiovascular warning
The most consequential point on this page has nothing to do with testosterone. The penile arteries are small, and when endothelial disease begins they narrow before the coronary arteries produce symptoms, which makes erectile dysfunction one of the first clinically visible signs of vascular disease.
A meta-analysis of 12 prospective cohort studies published in the Journal of the American College of Cardiology found erectile dysfunction associated with a relative risk of 1.48 (95% CI 1.25–1.74) for cardiovascular disease, 1.46 (1.31–1.63) for coronary heart disease, 1.35 (1.19–1.54) for stroke, and 1.19 (1.05–1.34) for all-cause mortality. In 300 consecutive men with chest pain and angiographically confirmed coronary disease, erectile dysfunction was present in 49%, and in 67% of those who had both it appeared before the cardiac symptoms, by a mean of 38.8 months (Montorsi and colleagues, European Urology, 2003). That is a referral-based angiographic series rather than a population cohort, so the interval is indicative rather than precise.
The association is strongest in younger men. In a population cohort followed for a decade, men aged 40 to 49 with erectile dysfunction had a coronary disease incidence roughly fifty times that of men the same age without it, while by age 70 the difference had almost vanished (Inman and colleagues, Mayo Clinic Proceedings, 2009). Erectile dysfunction arising in a man's forties or fifties is therefore a reason to assess cardiovascular risk — blood pressure, lipids, glucose, smoking, weight — and not only testosterone.
Psychogenic, vascular, hormonal
Psychogenic causes predominate in younger men: performance anxiety, situational or relationship-related difficulty, often with preserved morning and masturbatory erections. Vascular and other organic causes predominate with age and comorbidity, typically with gradual onset and loss of morning erections. Hormonal causes are the smallest group and usually present with reduced desire alongside. Percentage breakdowns for these three groups could not be verified and are not published here, though the pattern itself is well established clinically.
The useful distinction is between sudden onset with preserved morning erections and situational variability, which points away from a vascular cause, and gradual onset with absent morning erections against a background of cardiovascular risk factors, which points toward one.
The other half of the bed
Testosterone's clearest effect in men is on desire rather than erections, and the same holds in women: the one indication with good randomised evidence behind it is distressing low sexual desire after menopause, not energy or ageing. Two separate evidence bases, in two sexes, converge on the same conclusion about what the hormone does. Couples often arrive at this subject together, and what testosterone is for in women, what the evidence supports, and what a man using a topical gel needs to know about transferring it to a partner are covered in testosterone in women. Which of the four systems is actually failing, and whether testosterone has anything to offer it, is what the assessment at the practice is for.
Questions patients ask
Testosterone will cure my erectile dysfunction.
Usually not, and the effect that does exist is modest and concentrated in marked deficiency.
What the evidence showsTRAVERSE found no significant difference in erectile function (p=0.443) in 5,246 older men, despite improvements in desire and sexual activity. The Testosterone Trials, in more clearly deficient men, found improvement of 2.64 (95% CI 1.68–3.61). Xu and colleagues (2024), pooling 12 trials in 1,466 men, found a weighted mean improvement of 3.26 IIEF points (95% CI 1.65–4.88). Corona and colleagues (European Urology), pooling 14 trials in 2,298 men, found 2.95 points (95% CI 1.86–4.03) below 8 nmol/L against 1.47 (95% CI 0.90–2.03) below 12 (Q=5.61, p=0.02).
What remains uncertainWhether 8 nmol/L is a biological threshold or a convenient cut point, whether a 3-point IIEF change is what a man would call meaningful, and which individual men fall into the responsive group.
Bottom lineWorth measuring testosterone. If erections are the main problem, testosterone alone is a poor bet.
Moderate
Adding testosterone improves how well sildenafil works.
The best trial found no benefit.
What the evidence showsSpitzer and colleagues, Annals of Internal Medicine 2012, randomised around 140 men aged 40 to 70 with low testosterone and erectile dysfunction, already optimised on sildenafil, to testosterone or placebo for fourteen weeks. The mean difference was 2.2 points (95% CI −0.8 to 5.1, p=0.150), with desire, intercourse frequency and satisfaction similarly unchanged. Older, smaller positive trials exist, including one from 2004 in hypogonadal non-responders.
What remains uncertainWhether a more deficient subgroup would respond.
Bottom lineMixed evidence with the best trial negative, and not in itself a reason to add testosterone.
Limited
Low desire means low testosterone.
Desire is testosterone's most reliable effect and still has many other causes.
What the evidence showsLow sexual desire was one of three symptoms, from 32 screened in 3,369 men, independently associated with testosterone in the European Male Ageing Study. The Testosterone Trials found a desire treatment effect of 2.93 (95% CI 2.13–3.74, p<0.001), and TRAVERSE found significant improvement in desire. Desire is also affected by relationship factors, depression, medications including SSRIs, stress, sleep and chronic illness.
What remains uncertainHow much desire is hormonal rather than relational, psychological or medication-related in any individual.
Bottom lineThe one sexual outcome testosterone reliably moves, in men who are deficient. Normal testosterone with low desire means the cause lies elsewhere.
Strong
Masturbation lowers testosterone, and abstinence raises it.
Neither claim is supported, and the source of both was retracted.
What the evidence showsThe claim traces to a 2003 study of 28 men reporting a single transient peak at day seven of abstinence, reaching about 145.7% of baseline, which did not persist with continued abstinence. The paper was retracted, for duplicate publication rather than fraud, and it was small, unblinded and unreplicated. Fact-checkers have rated the popular claim of a 45% testosterone increase from seven days false. No credible evidence links ejaculation frequency to lasting testosterone changes in normal men.
What remains uncertainWhether the transient day-seven observation was real at all, given the study's fate.
Bottom lineEjaculation frequency is not a testosterone variable.
Strong
Testosterone improves orgasm, stamina, penile sensitivity or adult penis size.
None of these is a documented effect.
What the evidence showsAndrogens drive genital development in fetal life and puberty, and no randomised or population evidence shows circulating testosterone changing penis size in men who have already developed. Across trials, testosterone moves desire and sexual activity while leaving the mechanics unchanged. Orgasm quality, ejaculatory latency and penile sensitivity are barely measured endpoints, and ejaculatory latency is governed by different neurology.
What remains uncertainAlmost everything, because these outcomes are not studied.
Bottom lineNot effects to expect from treatment.
Limited
Erectile dysfunction is a sexual problem rather than a medical one.
In a man in his forties or fifties it is often the first visible sign of vascular disease.
What the evidence showsA meta-analysis of 12 prospective cohorts in the Journal of the American College of Cardiology found erectile dysfunction associated with a relative risk of 1.48 (95% CI 1.25–1.74) for cardiovascular disease, 1.46 (1.31–1.63) for coronary heart disease, 1.35 (1.19–1.54) for stroke and 1.19 (1.05–1.34) for all-cause mortality. In a population cohort, men aged 40 to 49 with erectile dysfunction had roughly fifty times the coronary disease incidence of men the same age without it, with the gap almost vanishing by 70.
What remains uncertainWhether the roughly three-year lead time generalises. Montorsi's 38.8-month mean comes from men already referred for angiography rather than from a population cohort.
Bottom lineNew erectile dysfunction in a middle-aged man warrants a cardiovascular assessment, not only a hormone panel.
Strong
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.
Our endocrinologists evaluate low testosterone in La Jolla, La Mesa and Poway: low testosterone care at Diabetes & Endocrine Specialists.


